HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Take the CME quiz: Vol. 15 No. 1, January 2006 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Varma, S. K. Search for Related Content PubMed Articles by Varma, S. K. Related Collections Bioethics Clinical Pharmacology and Therapeutics Endocrinology

AAP Grand Rounds 15:9-10 (2006)
© 2006 American Academy of Pediatrics

Long-Term Growth Hormone Treatment of Idiopathic Short Stature

The first 20% of the full text of this article appears below.

These authors, including researchers from the University of Arkansas, Little Rock, and Genentech, Inc., South San Francisco, Calif., and consultants from the United States and Brazil, evaluated data from the observational National Cooperative Growth Study (NCGS), a multi-center postmarketing surveillance study established by Genentech in 1985 to evaluate the use, safety, and efficacy of Genentech’s biosynthetic human growth hormone (GH) products for the treatment of idiopathic short stature (ISS) in more than 8000 North American children. ISS is defined as short stature of unknown etiology in a child whose height is more than 2.25 Standard Deviation scores (SDS) below the mean and who is considered unlikely to reach a normal adult height. Data from these patients were assessed for safety, and efficacy analysis was performed on 3 subcohorts of patients based upon age and pubertal status at baseline. Patients were identified as having ISS if they met any of the following 3 criteria: a maximum stimulated growth hormone of 10 ng/ml or greater with text information confirming a physician diagnosis of ISS; a maximum stimulated GH of 10 ng/ml or greater and the . . . [Full Text of this Article]

Surendra K. Varma, MD, FAAP

Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX

 

This article has been cited by other articles:

				S. K. Varma Growing Numbers for Idiopathic Short Stature Growth Hormone Therapy AAP Grand Rounds, February 1, 2007; 17(2): 19 - 20. [Full Text] [PDF]